What is Linzagolix, the oral GnRH antagonist used for gynaecological conditions?

Linzagolix (brand name Yselty) is an oral gonadotrophin-releasing hormone (GnRH) antagonist developed to treat hormone-dependent gynaecological conditions, most notably endometriosis-associated pain and uterine fibroids. It represents a newer generation of reproductive health medicines designed to suppress oestrogen in a controlled and reversible way, without the injections required by older therapies.

How Linzagolix works

GnRH antagonists act on the hypothalamic–pituitary–gonadal axis, a hormonal signalling pathway that regulates oestrogen production.

Linzagolix works by:

• Blocking GnRH receptors in the pituitary gland

• Reducing the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH)

• Lowering ovarian oestrogen production
  

Because endometriosis lesions and fibroids are oestrogen-dependent, reducing circulating oestrogen can significantly ease pain and bleeding.

Unlike earlier GnRH agonists, Linzagolix:

• Does not cause an initial hormone “flare”

• Begins suppressing oestrogen rapidly

• Is taken once daily as a tablet
  

Dose flexibility and “add-back” therapy

A defining feature of Linzagolix is its dose-dependent oestrogen suppression.

• Lower doses partially suppress oestrogen, often avoiding menopausal-type side effects

• Higher doses produce near-complete suppression and may be paired with add-back therapy (small amounts of oestrogen and progestogen) to protect bone density and reduce symptoms such as hot flushes
  

This flexibility allows treatment to be tailored to symptom severity, duration of use and individual risk factors.

Approved uses

Endometriosis

Linzagolix is approved in the UK and parts of Europe for the treatment of moderate to severe endometriosis-associated pain in adult women of reproductive age.

Clinical trials showed significant reductions in:

• Pelvic pain

• Dysmenorrhoea (painful periods)

• Non-menstrual pelvic pain
  

Uterine fibroids

The drug is also approved in some regions for fibroid-related heavy menstrual bleeding, again using dose adjustment and add-back therapy where appropriate.

How it differs from older treatments

Traditional options for endometriosis and fibroids have included:

• Injectable GnRH agonists

• Combined hormonal contraception

• Progestogens

• Surgery
  

Linzagolix differs in several key ways:

• Oral, not injectable

• Reversible suppression without long wash-out periods

• Reduced risk of profound hypo-oestrogenism when used at lower doses

• Potential for longer-term use with add-back therapy
  

This makes it particularly valuable for patients seeking medical alternatives to surgery or those who cannot tolerate other hormonal treatments.

Side effects and safety considerations

As with all oestrogen-suppressing therapies, side effects can occur, particularly at higher doses. These may include:

• Hot flushes

• Headache

• Fatigue

• Reduced bone mineral density with prolonged use
  

Bone health monitoring is recommended for extended treatment, especially when linzagolix is used without add-back therapy.

Importantly, the medication is not a contraceptive, and ovulation may still occur at lower doses.

Why Linzagolix matters

Linzagolix is part of a broader shift towards more precise, patient-centred hormone therapies in women’s health. By allowing clinicians to fine-tune oestrogen suppression, it addresses long-standing trade-offs between symptom control and quality of life.

While it is not a cure for endometriosis or fibroids, it offers a meaningful new option for managing chronic, debilitating conditions that have historically been under-treated and under-researched.

As research continues, oral GnRH antagonists like Linzagolix are expected to play an increasingly central role in non-surgical gynaecological care.